Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort
| dc.contributor.author | Buzón Martín, Luis | |
| dc.contributor.author | Bernardino, José I. | |
| dc.contributor.author | Galindo Puerto, María José | |
| dc.contributor.author | Martín Torres, Juan | |
| dc.contributor.author | Alemán Valls, María Remedios | |
| dc.contributor.author | Torralba González de Suso, Miguel | |
| dc.contributor.author | Díaz de Santiago, Alberto | |
| dc.contributor.author | Fanjul, Francisco | |
| dc.contributor.author | Rodríguez, Adrián | |
| dc.contributor.author | Cabello Úbeda, Alfonso | |
| dc.contributor.author | Pedrero Tomé, Roberto | |
| dc.contributor.author | Crusells Canales, María José | |
| dc.contributor.author | Calzado Isbert, Sonia | |
| dc.contributor.author | Aguilera García, María | |
| dc.contributor.author | Hidalgo Tenorio, Carmen | |
| dc.contributor.author | Morano, Luis | |
| dc.contributor.author | Vinuesa García, David | |
| dc.contributor.author | Andrés David, Carlos de | |
| dc.contributor.author | Bernal Morell, Enrique | |
| dc.contributor.author | Martínez Álvarez, Rosa María | |
| dc.contributor.author | Cabello Clotet, Noemí | |
| dc.contributor.author | Tiraboschi, Juan Manuel | |
| dc.contributor.author | Gimeno García, Alejandra | |
| dc.contributor.author | Vivancos, María Jesús | |
| dc.contributor.author | Troya, Jesús | |
| dc.contributor.author | Relativity Cohort Group | |
| dc.date.accessioned | 2026-07-01T11:32:46Z | |
| dc.date.available | 2026-07-01T11:32:46Z | |
| dc.date.issued | 2025-10-22 | |
| dc.date.updated | 2026-05-14T12:51:49Z | |
| dc.description.abstract | Objectives:Long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) provides an alternative to daily therapy for people with HIV (PWH) with virologic suppression. Although genotypic testing is recommended before switching, its real-world clinical value is unclear. We assessed outcomes after switching to LAI CAB+RPV with or without available genotypes in the Spanish RELATIVITY cohort. Design:RELATIVITY is a multicenter, ambispective cohort study assessing the effectiveness and safety of LAI CAB+RPV in adults with HIV across 58 centers in Spain. Methods:Posthoc analysis of 3146 participants, focusing on the availability of genotypic resistance data before switching. Results:Of the 3146 participants, 53.5% (n = 1682) did not have genotypes available. The median follow-up was 13.3 months [interquartile range (IQR) 8.6, 18.9] in the no-genotype group and 14.9 months (IQR 9.0, 19.2) in the genotype group (P = 0.003). Both groups maintained high virological suppression rates (>93%) up to the 23rd month of follow-up, with no significant differences observed in virological or immunological outcomes. Virologic failure rates (0.5% vs. 1.0%; P = 0.476) and permanent discontinuation rates (6.1% vs. 6.6%; P = 0.804) were similar. Of the 20 participants with virologic failure, 12 had genotype data. After resuming oral antiretroviral therapy, 8 of those with and 4 of those without the genotype achieved undetectable viral loads. Adherence to injection schedules and changes in body mass index were comparable. Conclusions:In this large real-world cohort, the absence of genotypic data did not affect LAI CAB+RPV effectiveness in virologically suppressed PWH. Limitations, including ambispective design, short follow-up, and low non-B subtype prevalence, may limit generalizability. | |
| dc.format.extent | 14 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.issn | 1473-5571 | |
| dc.identifier.pmid | 41183264 | |
| dc.identifier.uri | https://hdl.handle.net/2445/230341 | |
| dc.language.iso | eng | |
| dc.publisher | Wolters Kluwer Health | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1097/QAD.0000000000004388 | |
| dc.relation.ispartof | AIDS, 2025, vol. 40, num. 4, p. 414-427 | |
| dc.relation.uri | https://doi.org/10.1097/QAD.0000000000004388 | |
| dc.rights | cc by-nc-nd (c) Buzón Martín, Luis et al., 2026 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | |
| dc.subject.classification | Antiretrovirals | |
| dc.subject.classification | Medicació transdèrmica | |
| dc.subject.other | Antiretroviral agents | |
| dc.subject.other | Transdermal medication | |
| dc.title | Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1
Carregant...
- Nom:
- genotyping_not_required_for_sustained.2.pdf
- Mida:
- 714.12 KB
- Format:
- Adobe Portable Document Format